| Paul Copperman, DO | |
|
420 S 5th Ave, West Reading, PA 19611-2143 | |
| (484) 628-3637 | |
| (484) 628-8773 |
| Full Name | Paul Copperman |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 6 Years |
| Location | 420 S 5th Ave, West Reading, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205329117 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | OT018591 (Pennsylvania) | Secondary |
| 207P00000X | Emergency Medicine | 20A18998 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sutter Roseville Medical Center | Roseville, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cep America - California | 6103739131 | 954 |
News Archive
This year, as has been the case so often in the past, their target is President Obama's health care reform law. If it is not repealed or defunded or delayed or otherwise left bleeding in the public square, they will not pass a spending bill needed to keep the government open past Sept. 30. And if that doesn't cripple the health law (which it won't), they will resort to the far more serious threat of default, refusing to raise the nation's debt ceiling, no matter the catastrophe that would cause (9/14).
Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received approval for three antiretroviral (ARV) therapies used to treat HIV/AIDS under the World Health Organization's (WHO) Prequalification of Medicines Programme. The products include:
Escherichia coli K1 (E. coli K1) continues to be a major threat to the health of young infants. Affecting the central nervous system, it causes neonatal meningitis by multiplying in immune cells, such as macrophages, and then disseminating into the bloodstream to subsequently invade the blood-brain barrier.
The George Washington University announced today its participation in a Sanofi COVID-19 vaccine clinical trial. GW was selected as one of approximately 25 sites in the United States to launch a phase 2 study for its adjuvanted recombinant protein-based COVID-19 vaccine candidate.
Bellicum Pharmaceuticals, Inc. today announced $4.5 million in Series A and Convertible Note funding. The new funds will be used to complete the company's ongoing Phase I/IIa trial of BP-GMAX-CD1 in patients with advanced, androgen independent prostate cancer, and to prepare for Phase IIb trials. The company anticipates reporting initial results of the Phase I/IIa trial in mid 2010.
› Verified 1 days ago
| Entity Name | Cep America - California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023063542 PECOS PAC ID: 6103739131 Enrollment ID: O20031106000520 |
News Archive
This year, as has been the case so often in the past, their target is President Obama's health care reform law. If it is not repealed or defunded or delayed or otherwise left bleeding in the public square, they will not pass a spending bill needed to keep the government open past Sept. 30. And if that doesn't cripple the health law (which it won't), they will resort to the far more serious threat of default, refusing to raise the nation's debt ceiling, no matter the catastrophe that would cause (9/14).
Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received approval for three antiretroviral (ARV) therapies used to treat HIV/AIDS under the World Health Organization's (WHO) Prequalification of Medicines Programme. The products include:
Escherichia coli K1 (E. coli K1) continues to be a major threat to the health of young infants. Affecting the central nervous system, it causes neonatal meningitis by multiplying in immune cells, such as macrophages, and then disseminating into the bloodstream to subsequently invade the blood-brain barrier.
The George Washington University announced today its participation in a Sanofi COVID-19 vaccine clinical trial. GW was selected as one of approximately 25 sites in the United States to launch a phase 2 study for its adjuvanted recombinant protein-based COVID-19 vaccine candidate.
Bellicum Pharmaceuticals, Inc. today announced $4.5 million in Series A and Convertible Note funding. The new funds will be used to complete the company's ongoing Phase I/IIa trial of BP-GMAX-CD1 in patients with advanced, androgen independent prostate cancer, and to prepare for Phase IIb trials. The company anticipates reporting initial results of the Phase I/IIa trial in mid 2010.
› Verified 1 days ago
| Entity Name | Regents Of The Univ Of Ca |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013906973 PECOS PAC ID: 3375456619 Enrollment ID: O20031111000892 |
News Archive
This year, as has been the case so often in the past, their target is President Obama's health care reform law. If it is not repealed or defunded or delayed or otherwise left bleeding in the public square, they will not pass a spending bill needed to keep the government open past Sept. 30. And if that doesn't cripple the health law (which it won't), they will resort to the far more serious threat of default, refusing to raise the nation's debt ceiling, no matter the catastrophe that would cause (9/14).
Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received approval for three antiretroviral (ARV) therapies used to treat HIV/AIDS under the World Health Organization's (WHO) Prequalification of Medicines Programme. The products include:
Escherichia coli K1 (E. coli K1) continues to be a major threat to the health of young infants. Affecting the central nervous system, it causes neonatal meningitis by multiplying in immune cells, such as macrophages, and then disseminating into the bloodstream to subsequently invade the blood-brain barrier.
The George Washington University announced today its participation in a Sanofi COVID-19 vaccine clinical trial. GW was selected as one of approximately 25 sites in the United States to launch a phase 2 study for its adjuvanted recombinant protein-based COVID-19 vaccine candidate.
Bellicum Pharmaceuticals, Inc. today announced $4.5 million in Series A and Convertible Note funding. The new funds will be used to complete the company's ongoing Phase I/IIa trial of BP-GMAX-CD1 in patients with advanced, androgen independent prostate cancer, and to prepare for Phase IIb trials. The company anticipates reporting initial results of the Phase I/IIa trial in mid 2010.
› Verified 1 days ago
| Entity Name | Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952998973 PECOS PAC ID: 8022922475 Enrollment ID: O20031118001149 |
News Archive
This year, as has been the case so often in the past, their target is President Obama's health care reform law. If it is not repealed or defunded or delayed or otherwise left bleeding in the public square, they will not pass a spending bill needed to keep the government open past Sept. 30. And if that doesn't cripple the health law (which it won't), they will resort to the far more serious threat of default, refusing to raise the nation's debt ceiling, no matter the catastrophe that would cause (9/14).
Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received approval for three antiretroviral (ARV) therapies used to treat HIV/AIDS under the World Health Organization's (WHO) Prequalification of Medicines Programme. The products include:
Escherichia coli K1 (E. coli K1) continues to be a major threat to the health of young infants. Affecting the central nervous system, it causes neonatal meningitis by multiplying in immune cells, such as macrophages, and then disseminating into the bloodstream to subsequently invade the blood-brain barrier.
The George Washington University announced today its participation in a Sanofi COVID-19 vaccine clinical trial. GW was selected as one of approximately 25 sites in the United States to launch a phase 2 study for its adjuvanted recombinant protein-based COVID-19 vaccine candidate.
Bellicum Pharmaceuticals, Inc. today announced $4.5 million in Series A and Convertible Note funding. The new funds will be used to complete the company's ongoing Phase I/IIa trial of BP-GMAX-CD1 in patients with advanced, androgen independent prostate cancer, and to prepare for Phase IIb trials. The company anticipates reporting initial results of the Phase I/IIa trial in mid 2010.
› Verified 1 days ago
| Entity Name | Cep America - California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548667843 PECOS PAC ID: 6103739131 Enrollment ID: O20040121000458 |
News Archive
This year, as has been the case so often in the past, their target is President Obama's health care reform law. If it is not repealed or defunded or delayed or otherwise left bleeding in the public square, they will not pass a spending bill needed to keep the government open past Sept. 30. And if that doesn't cripple the health law (which it won't), they will resort to the far more serious threat of default, refusing to raise the nation's debt ceiling, no matter the catastrophe that would cause (9/14).
Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received approval for three antiretroviral (ARV) therapies used to treat HIV/AIDS under the World Health Organization's (WHO) Prequalification of Medicines Programme. The products include:
Escherichia coli K1 (E. coli K1) continues to be a major threat to the health of young infants. Affecting the central nervous system, it causes neonatal meningitis by multiplying in immune cells, such as macrophages, and then disseminating into the bloodstream to subsequently invade the blood-brain barrier.
The George Washington University announced today its participation in a Sanofi COVID-19 vaccine clinical trial. GW was selected as one of approximately 25 sites in the United States to launch a phase 2 study for its adjuvanted recombinant protein-based COVID-19 vaccine candidate.
Bellicum Pharmaceuticals, Inc. today announced $4.5 million in Series A and Convertible Note funding. The new funds will be used to complete the company's ongoing Phase I/IIa trial of BP-GMAX-CD1 in patients with advanced, androgen independent prostate cancer, and to prepare for Phase IIb trials. The company anticipates reporting initial results of the Phase I/IIa trial in mid 2010.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Paul Copperman, DO Po Box 13579, Reading, PA 19612-3579 Ph: () - | Paul Copperman, DO 420 S 5th Ave, West Reading, PA 19611-2143 Ph: (484) 628-3637 |
News Archive
This year, as has been the case so often in the past, their target is President Obama's health care reform law. If it is not repealed or defunded or delayed or otherwise left bleeding in the public square, they will not pass a spending bill needed to keep the government open past Sept. 30. And if that doesn't cripple the health law (which it won't), they will resort to the far more serious threat of default, refusing to raise the nation's debt ceiling, no matter the catastrophe that would cause (9/14).
Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received approval for three antiretroviral (ARV) therapies used to treat HIV/AIDS under the World Health Organization's (WHO) Prequalification of Medicines Programme. The products include:
Escherichia coli K1 (E. coli K1) continues to be a major threat to the health of young infants. Affecting the central nervous system, it causes neonatal meningitis by multiplying in immune cells, such as macrophages, and then disseminating into the bloodstream to subsequently invade the blood-brain barrier.
The George Washington University announced today its participation in a Sanofi COVID-19 vaccine clinical trial. GW was selected as one of approximately 25 sites in the United States to launch a phase 2 study for its adjuvanted recombinant protein-based COVID-19 vaccine candidate.
Bellicum Pharmaceuticals, Inc. today announced $4.5 million in Series A and Convertible Note funding. The new funds will be used to complete the company's ongoing Phase I/IIa trial of BP-GMAX-CD1 in patients with advanced, androgen independent prostate cancer, and to prepare for Phase IIb trials. The company anticipates reporting initial results of the Phase I/IIa trial in mid 2010.
› Verified 1 days ago
Liza Gergenti, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 420 S 5th Ave, West Reading, PA 19611 Phone: 484-628-3528 | |
Joshua Adam Werner, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 420 S 5th Ave, West Reading, PA 19611 Phone: 484-628-3637 | |
Eric Smith, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 420 S 5th Ave, West Reading, PA 19611 Phone: 484-628-8000 | |
James Sullivan, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 420 S 5th Ave, West Reading, PA 19611 Phone: 484-628-8000 | |
Ray Morganti, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 6th Ave & Spruce St, West Reading, PA 19611 Phone: 610-988-8218 | |
Dr. Joseph Patrick Corcoran Iv, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 420 S 5th Ave, West Reading, PA 19611 Phone: 484-628-8000 | |
Memu-iye Kamara, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 420 S 5th Ave, West Reading, PA 19611 Phone: 484-628-8000 |